share_log

Reneo Pharmaceuticals (NASDAQ:RPHM) Trading Up 2%

Reneo Pharmaceuticals (NASDAQ:RPHM) Trading Up 2%

Reneo Pharmicals（納斯達克股票代碼：RPHM）交易上漲2％
Defense World ·  2023/01/25 02:41

Reneo Pharmaceuticals, Inc. (NASDAQ:RPHM – Get Rating)'s stock price was up 2% during trading on Tuesday . The stock traded as high as $2.64 and last traded at $2.55. Approximately 125,887 shares traded hands during trading, an increase of 180% from the average daily volume of 44,959 shares. The stock had previously closed at $2.50.

Reneo Pharmicals, Inc.（納斯達克股票代碼：RPHM — 獲取評級）的股價在週二的交易中上漲了2％。該股交易價格高達2.64美元，最後一次交易價格爲2.55美元。交易期間約有125,887股交易，較平均每日交易量44,959股增加了180％。該股此前收於2.50美元。

Reneo Pharmaceuticals Stock Up 2.0 %

Reneo Pharmicals股價上漲2.

The company's 50 day moving average price is $2.30 and its 200 day moving average price is $2.91. The firm has a market capitalization of $62.55 million, a price-to-earnings ratio of -1.28 and a beta of 0.50.

該公司的50天移動平均價格爲2.30美元，其200天移動平均線價格爲2.91美元。該公司的市值爲6,255萬美元，市盈率爲-1.28，beta值爲0.50。

Get
獲取
Reneo Pharmaceuticals
Reneo 製藥
alerts:
警報：

Reneo Pharmaceuticals (NASDAQ:RPHM – Get Rating) last issued its earnings results on Tuesday, November 8th. The company reported ($0.53) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.58) by $0.05. As a group, analysts expect that Reneo Pharmaceuticals, Inc. will post -2.16 earnings per share for the current year.

Reneo Pharmicals（納斯達克股票代碼：RPHM — 獲取評級）最後一次發佈財報是在11月8日星期二。該公司公佈的本季度每股收益（EPS）（0.53美元），比市場普遍預期的（0.58美元）高出0.05美元。作爲一個整體，分析師預計，Reneo Pharmicals, Inc.將公佈本年度的每股收益爲-2.16％。

Institutional Inflows and Outflows

機構流入和流出

Several institutional investors have recently made changes to their positions in RPHM. Renaissance Technologies LLC purchased a new position in shares of Reneo Pharmaceuticals during the second quarter worth $61,000. Dimensional Fund Advisors LP purchased a new position in shares of Reneo Pharmaceuticals during the third quarter worth $62,000. Federated Hermes Inc. increased its holdings in Reneo Pharmaceuticals by 76.5% in the second quarter. Federated Hermes Inc. now owns 30,000 shares of the company's stock valued at $80,000 after buying an additional 13,000 shares in the last quarter. Bank of America Corp DE raised its position in shares of Reneo Pharmaceuticals by 24.0% in the first quarter. Bank of America Corp DE now owns 40,878 shares of the company's stock worth $121,000 after acquiring an additional 7,914 shares during the period. Finally, UBS Group AG boosted its stake in shares of Reneo Pharmaceuticals by 5,012.5% during the 2nd quarter. UBS Group AG now owns 54,550 shares of the company's stock worth $145,000 after acquiring an additional 53,483 shares in the last quarter. Hedge funds and other institutional investors own 75.61% of the company's stock.
幾位機構投資者最近改變了他們在RPHM的頭寸。Renaissance Technologies LLC在第二季度購買了價值61,000美元的Reneo Pharmicals股票的新Dimensional Fund Advisors LP在第三季度購買了價值62,000美元的Reneo Pharmicals股票的新頭寸聯邦愛馬仕公司在第二季度將其在Reneo Pharmicals的持股量增加了76.5％。聯邦愛馬仕公司在上個季度又購買了13,000股股票後，現在擁有該公司3萬股股票，價值8萬美元。美國銀行德意志銀行在第一季度將其在Reneo Pharmicals的股票頭寸上調了24.0％。美國銀行德意志銀行在此期間又收購了7,914股股票後，現在擁有該公司40,878股股票，價值12.1萬美元。最後，瑞銀集團股份公司在第二季度將其在Reneo Pharmicals的股份增加了5,012.5％。瑞銀集團股份公司在上個季度又收購了53,483股股票後，現在擁有該公司54,550股股票，價值14.5萬美元。對沖基金和其他機構投資者擁有該公司75.61％的股票。

About Reneo Pharmaceuticals

關於 Reneo 製藥

(Get Rating)

（獲取評分）

Reneo Pharmaceuticals, Inc, a clinical-stage pharmaceutical company, focuses on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases. Its lead product candidate is REN001, a potent and selective agonist of the peroxisome proliferator-activated receptor delta that is in clinical development for genetic mitochondrial diseases comprising primary mitochondrial myopathies and long-chain fatty acid oxidation disorders.

Reneo Pharmicals, Inc是一家處於臨床階段的製藥公司，專注於罕見遺傳線粒體疾病患者的療法的開發和商業化。其主要候選產品是 REN001，這是一種強效的選擇性過氧化物酶體增殖物激活受體 delta 的激動劑，正在臨床開發用於遺傳線粒體疾病，包括原發性線粒體肌病和長鏈脂肪酸氧化障礙。

Further Reading

進一步閱讀

  • Get a free copy of the StockNews.com research report on Reneo Pharmaceuticals (RPHM)
  • EVgo Stock is Charged Up to Ride the EV Adoption Wave
  • Qualcomm Gets a Boost from Analysts, but is it Time to Buy?
  • High-Yield, Deep-Value Verizon Puts In A Bottom
  • Can Coty Stock Emerge in 2023 With Upside
  • Should You Bet Against The Nasdaq 100 With This Inverse ETF?
  • 免費獲取 StockNews.com 關於 Reneo Pharmicals（RPHM）的研究報告的副本
  • EvGo 股票備受衝擊，可以順應電動汽車的採用浪潮
  • 高通得到了分析師的提振，但現在是買入的時候了嗎？
  • 高收益、深層價值的Verizon跌入谷底
  • 科蒂股票能否在 2023 年出現上行空間
  • 你應該用這個反向ETF押注納斯達克100嗎？

Receive News & Ratings for Reneo Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Reneo Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

接收Reneo Pharmicals每日的新聞和收視率 -在下面輸入您的電子郵件地址，通過Marketbeat.com的免費每日電子郵件時事通訊接收Reneo Pharmicals及相關公司最新新聞和分析師評級的簡明每日摘要。

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論